David Steinberg
Stock Analyst at Jefferies
(2.87)
# 1,571
Out of 5,126 analysts
33
Total ratings
64%
Success rate
26.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Steinberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHC Bausch Health Companies | Downgrades: Hold | $12 → $8 | $5.88 | +36.05% | 7 | Feb 6, 2025 | |
| PRGO Perrigo Company | Upgrades: Buy | $45 → $63 | $14.64 | +330.33% | 8 | Sep 30, 2021 | |
| SUPN Supernus Pharmaceuticals | Upgrades: Buy | $25 → $40 | $51.65 | -22.56% | 11 | Apr 13, 2021 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $151 → $188 | $165.50 | +13.60% | 5 | Oct 9, 2020 | |
| OCUL Ocular Therapeutix | Initiates: Buy | $8 | $9.16 | -12.66% | 1 | Mar 17, 2020 | |
| SVRA Savara | Initiates: Buy | $20 | $5.30 | +277.36% | 1 | Sep 22, 2017 |
Bausch Health Companies
Feb 6, 2025
Downgrades: Hold
Price Target: $12 → $8
Current: $5.88
Upside: +36.05%
Perrigo Company
Sep 30, 2021
Upgrades: Buy
Price Target: $45 → $63
Current: $14.64
Upside: +330.33%
Supernus Pharmaceuticals
Apr 13, 2021
Upgrades: Buy
Price Target: $25 → $40
Current: $51.65
Upside: -22.56%
Jazz Pharmaceuticals
Oct 9, 2020
Maintains: Buy
Price Target: $151 → $188
Current: $165.50
Upside: +13.60%
Ocular Therapeutix
Mar 17, 2020
Initiates: Buy
Price Target: $8
Current: $9.16
Upside: -12.66%
Savara
Sep 22, 2017
Initiates: Buy
Price Target: $20
Current: $5.30
Upside: +277.36%